Literature DB >> 2278904

Effect of albendazole on human hydatid cysts: an ultrastructural study.

K S Richards1, D L Morris.   

Abstract

Five patients with hepatic (3), pelvic (1) or spinal (1) hydatid cysts received 10 mg/kg/d albendazole for 1-3 months prior to surgery. Daughter cysts were present in the spinal hydatid and in one patient with hepatic disease. Electron microscope examination of the cyst tissue of the pelvic and the 2 hepatic cysts lacking daughter cysts showed no evidence of germinal layer, and the protoscoleces were dead. The primary cyst of the hepatic hydatid with daughter cysts (1 month therapy) was also judged dead but some pieces of the daughter cyst germinal layer appeared normal and had unaffected protoscoleces. The daughter cyst tissue of the spinal hydatid (3 month therapy) appeared normal and the protoscoleces viable. In view of the undetermined viability of human hydatids before chemotherapy, treatment of longer than 1 month is advocated for hepatic cysts, particularly if daughter cysts are present, and longer therapy is indicated for spinal disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2278904      PMCID: PMC2423562          DOI: 10.1155/1990/47243

Source DB:  PubMed          Journal:  HPB Surg        ISSN: 0894-8569


  3 in total

1.  Efficacies of albendazole sulfoxide and albendazole sulfone against In vitro-cultivated Echinococcus multilocularis metacestodes.

Authors:  K Ingold; P Bigler; W Thormann; T Cavaliero; B Gottstein; A Hemphill
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  A combined medical and surgical approach to hydatid disease: 12 years' experience at the Hospital for Tropical Diseases, London.

Authors:  H M Ayles; E L Corbett; I Taylor; A G A Cowie; J Bligh; K Walmsley; A D M Bryceson
Journal:  Ann R Coll Surg Engl       Date:  2002-03       Impact factor: 1.891

3.  Treatment of the residual cavity during hepatic hydatidosis surgery: a cohort study of capitonnage vs. omentoplasty.

Authors:  Carlos Manterola; Juan Carlos Roa; Sebastián Urrutia
Journal:  Surg Today       Date:  2013-04-06       Impact factor: 2.549

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.